NSPR InspireMD, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1433607 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY35.8%
TTM net income YoY-7.2%
TTM EPS YoY30.5%
Revenue 3-yr CAGR24.5%
Net income 3-yr CAGR—
Margins
Gross margin12.6%
Operating margin-477.8%
Net margin-469.1%
FCF margin-420.3%
EBITDA margin4,031.1%
Returns
ROE-115.4%
ROA-88.4%
ROIC (approx.)-2,478.3%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets35.2%
Debt / equity0.00x
Current ratio2.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-11.3%
Payout ratio—
Capex / revenue11.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.24M | $1.77M | $3.40M | $3.15M | $2.52M | $1.78M | $1.53M | $1.95M |
| Cost of revenue | $2.00M | $2.54M | $2.71M | $1.97M | $1.66M | $1.47M | $1.24M | $1.48M |
| Gross profit | $240,000 | -$774,000 | $687,000 | $1.18M | $864,000 | $313,000 | $292,000 | $469,000 |
| R&D expense | $3.27M | $4.29M | $4.76M | $3.48M | $3.63M | $3.83M | $4.06M | $3.69M |
| SG&A expense | $3.45M | $4.16M | $4.72M | $4.55M | $5.89M | $5.33M | $4.94M | $4.23M |
| Operating income | -$9.95M | -$14.45M | -$13.98M | -$12.08M | -$13.05M | -$13.02M | -$11.46M | -$9.37M |
| Net income | -$9.76M | -$14.32M | -$13.69M | -$11.76M | -$12.71M | -$13.15M | -$11.17M | -$9.17M |
| EBITDA | -$9.79M | -$14.29M | -$13.83M | $463.58M | -$12.92M | -$12.91M | -$11.36M | $270.43M |
| EPS (basic) | -0.12 | -0.17 | -0.16 | — | -0.17 | -0.26 | 0.22 | — |
| EPS (diluted) | -0.12 | -0.17 | -0.16 | — | -0.17 | -0.26 | 0.22 | — |
| Weighted avg. shares (diluted) | 85.62M | 84.66M | 83.80M | — | 73.47M | 51.00M | 49.99M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $19.25M | $15.15M | $11.36M | $8.94M | $63.40M | $11.51M | $12.38M | $18.92M |
| Short-term investments | — | $15.27M | $30.21M | $45.27M | — | $7.87M | $13.70M | $15.72M |
| Receivables | $1.90M | $1.82M | $2.38M | $2.17M | $1.96M | $1.59M | $1.58M | $1.57M |
| Inventory | $2.99M | $2.70M | $3.04M | $3.40M | $3.61M | $3.05M | $2.82M | $2.57M |
| Current assets | $25.65M | $36.63M | $48.59M | $61.47M | $70.39M | $25.46M | $32.14M | $40.52M |
| PP&E, net | $3.95M | $3.86M | $3.65M | $3.58M | $3.40M | $3.10M | $2.74M | $2.37M |
| Total assets | $33.57M | $44.64M | $56.47M | $69.40M | $78.47M | $33.34M | $38.67M | $46.81M |
| Current liabilities | $8.57M | $9.65M | $9.44M | $10.71M | $10.82M | $9.07M | $7.37M | $7.68M |
| Total liabilities | $11.82M | $13.13M | $12.85M | $14.20M | $14.36M | $13.10M | $10.33M | $10.72M |
| Shareholders' equity | $21.75M | $31.51M | $43.62M | $55.20M | $64.11M | $20.24M | $28.34M | $36.09M |
| Shares outstanding | 47.12M | 46.92M | 46.84M | 43.53M | 41.92M | 32.55M | 29.75M | 26.61M |
| Cash flow statement | ||||||||
| Operating cash flow | -$10.63M | -$10.89M | -$12.34M | -$9.35M | -$8.63M | -$8.33M | -$8.79M | -$6.75M |
| Capital expenditure | $257,000 | $330,000 | $194,000 | $398,000 | $329,000 | $576,000 | $359,000 | $311,000 |
| Free cash flow | -$10.88M | -$11.22M | -$12.53M | -$9.74M | -$8.96M | -$8.91M | -$9.15M | -$7.06M |
| Investing cash flow | $14.72M | $14.65M | $14.78M | -$45.13M | $7.55M | $5.32M | $1.70M | $8.24M |
| Financing cash flow | — | — | — | $0 | $52.93M | $2.14M | $506,000 | $1.56M |
| Depreciation & amortization | $168,000 | $158,000 | $149,000 | $475.67M | $128,000 | $107,000 | $98,000 | $279.80M |
| Stock-based compensation | $3,000 | $2.22M | $2.10M | $2.85M | $3.54M | $3.21M | $2.73M | $2.35M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.